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model was constructed with four health states regarding survival
and irreversible adverse events. Health care costs and effects of
SBRT, proton therapy and carbon-ion therapy were compared
over a ﬁve-year time horizon. Transition probabilities were
derived from single-armed observational studies, as no compara-
tive studies were available. Utilities were collected in a cross-
sectional survey. Probabilistic sensitivity analysis was performed
to reﬂect parameter uncertainty. RESULTS: Preliminary results
showed that the expected total health care costs per patient for
SBRT were €18,366, for protons €24,267 and for carbon-ions
€26,720. The expected quality adjusted life-years (QALYs) were
2.24, 2.40 and 2.45 respectively. This resulted in an incremental
cost-effectiveness ratio (ICER) of €36,651 per QALY for protons
as opposed to SBRT, and an ICER of €44,668 per QALY for
carbon-ions as opposed to protons. For a ceiling ratio of €40,000
protons had the highest probability of being cost-effective (41%),
followed by carbon-ions (35%) and SBRT (24%). For a ceiling
ratio of €80,000 these probabilities were 42%, 52% and 6%
respectively. CONCLUSIONS: These preliminary results indicate
that PT is a potentially cost-effective treatment modality for
inoperable stage I NSCLC. However, caution is warranted, as the
differences are small and surrounded by considerable uncer-
tainty. More analyses will be performed of which the results are
presented at the conference. First, more advanced statistical tech-
niques are applied to synthesize the available evidence. Second,
for operable patients PT is compared to surgery. Third, the
cost-effectiveness of PT is assessed for stage III NSCLC. Finally,
expected value of perfect information analyses are presented to
support research decisions.
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Achieving complete cytogenetic response (CCyR) is associated
with superior progression-free survival in patients with CML [1].
How this endpoint affects cost has not been evaluated. OBJEC-
TIVES: To assess the cost needed to achieve one CCyR with
dasatinib 140 mg vs. imatinib 600 and 800 mg in imatinib-
resistant CP-CML, from the perspective of national health
insurance in the Czech Republic, Hungary and Romania.
METHODS: An economic analysis was conducted using the
number of patients needed to be treated (NNT) to achieve one
CCyR. The incremental cost for achieving CCyR in 15 months
was determined. CCyR rates for dasatinib 140 and imatinib
800 mg were based on a randomized phase 2 trial START-R [2].
Given no published data on imatinib 600 mg, its CCyR rate was
assumed to be the same as for imatinib 800 mg; an assumption in
favor of imatinib. Costs were based on reimbursed drug-prices
from national lists. In Hungary, reimbursed amounts for 600 or
800 mg of imatinib are the same. RESULTS: To achieve one
CCyR, NNT is 6,25 for imatinib and 2,5 for dasatinib. The costs
to achieve one CCyR during 15 months of therapy are CZK9,1
million (€363,172), HUF52.8 million (€218,492) and RON1.2
million (€334,146) lower for dasatinib compared to imatinib
800 mg. The economic advantage of dasatinib remains when
compared to imatinib 600 mg. The incremental costs to achieve
one CCyR between imatininb 600 mg and dasatinib are CZK5.7
million (€228,664), HUF52,8 million (€218,492) and RON0.7
million (€205,316). CONCLUSIONS: In imatinib-resistant
CP-CML patients, therapy with dasatinib provides better efﬁcacy
and lower cost compared to imatinib 600 and 800 mg in Central
and Eastern Europe to achieve one CCyR. The magnitude of the
advantage varies due to different pricing and ﬁnancing systems.
[1] Hughes et al. NEJM 2003;349:1423–32; [2] Kantarjian et al.
Blood 2007;109:5143–50.
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OBJECTIVES: Diabetes affects over 2.3 million people in UK;
approximately 10% have type 1 diabetes (T1DM). The aim of
this study was to evaluate the long-term cost and clinical out-
comes associated with lispro versus regular human insulin (RHI)
in the UK T1DM patients using the previously published and
validated CORE Diabetes Model. METHODS: Several clinical
trials have provided evidence that short-acting insulin analogs,
with improved pharmacokinetic properties, may have beneﬁts in
terms of glycaemic control (HbA1c) and hypoglycemic event
rates compared to mealtime human insulin. For the simulations,
clinical beneﬁts were derived from a recent Cochrane meta-
analysis which found the weighted mean difference in HbA1c to
be -0.1% (95% CI -0.2% to -0.0%) for treatment with lispro
versus RHI. Major hypoglycaemic event rates for lispro and RHI
were 21.8 and 46.1 per 100 patient-years, respectively. Current
prices of insulin lispro (Humalog), regular human insulin
(Humulin R) and basal NPH insulin (Humulin I) were obtained
from http://www.mims.co.uk. Complication costs and patient
management costs (screening and concomitant medications)
were derived from published sources. All costs were accounted in
2007 Pounds Sterling (£) from a National Health Service (NHS)
perspective. Future costs and clinical beneﬁts were discounted at
3.5% annually. RESULTS: Model projections indicated that
lispro was associated with a beneﬁt in quality-adjusted life
expectancy of approximately 0.10 QALYS versus RHI (7.60
versus 7.50 QALYs). Lifetime direct medical costs per patient
were lower with lispro treatment, £70,576 versus £72,529.
Lispro was projected to be dominant (lower cost: more beneﬁt)
compared to RHI. Results were robust to sensitivity analyses
including time horizon, discounting rates and scenarios assum-
ing beneﬁt only on glycaemic control or hypoglycemia rates.
CONCLUSIONS: The study suggests that lispro is likely to
improve quality-adjusted life expectancy and reduce costs in UK
patients with T1DM, due principally to beneﬁts in hypoglycemic
event rates.
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OBJECTIVES: To estimate the impact of overweight or obesity
on treatment costs(TCs) in diabetic patients in the United States.
METHODS: Five-year (2001–2005) pooled Medical Expendi-
ture Panel Survey data, a nationally representative sample of U.S.
A358 Abstracts
non-institutionalized population, was used. A total of 7396
adult diabetic patients were identiﬁed based on ICD-9-CM code
of 250 after excluding pregnant women and cancer patients.
These patients were classiﬁed as normal(body mass index-
(BMI):18.5 -< 25), overweight(BMI:25 -< 30), or obese(BMI:
30). TCs included all costs except for treatment of dental
problems or injuries. The impact of overweight/obesity on TCs at
various points of the cost distribution was estimated using the
weighted quantile regression model after adjusting for age,
gender, and other study variables. The effects of the study vari-
ables on the median TCs were investigated using the weighted
median regression. All costs were converted to 2005 U.S. dollars
using price indices. Data were analyzed using SAS and SUDAAN.
RESULTS: Compared with normal-weight patients, the incre-
mental TC attributable to overweight were signiﬁcantly higher
from $238, $268, $409, and $442 at the 10th, 25th, 50th, and 75th
percentile respectively. But incremental costs were diminished to
$270 at the 90th percentile because of high costs in normal
weight patients with severe comorbidities such as nephropathy.
Similar trends were found in obese-patients compared with
normal-patients, and attributable costs are bigger. Median TCs
were increased in women vs. men and Caucasian vs. African-
American, and as patients became older. CONCLUSIONS: The
impact of overweight or obesity on TCs in diabetic patients was
substantial especially in the lower tail of the TC distribution. The
study ﬁndings suggest that controlling of weight to reduce TC is
very important in most diabetic patients, but less important in
the upper tail of the TC distribution. The quantile regression
method is useful for estimating TCs at the different percentiles of
the skewed TC distribution.
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OBJECTIVES: To evaluate and compare the total costs relevant
to diabetes care in patients with type 2 diabetes mellitus (T2D)
treated with either Insulin glargine- or conventional basal insulin
(NPH)-based therapies from the perspective of the German statu-
tory health insurance (SHI). METHODS: LIVE-SPP (Long acting
Insulin glargine Versus NPH Cost Evaluation in SPecialised Prac-
tices) Study is a naturalistic, retrolective, multicenter study of
adult patients with T2D. Costs were evaluated from the German
SHI perspective in 2005. Average total costs per patient for
Insulin glargine-based vs. NPH-based therapies were compared
over the 20-month period using multivariate general linear mod-
elling (GLM). Potential confounders tested were age, gender,
BMI, HbA1c, FBG, duration of diabetes, duration of insulin
pre-treatment, and number of diabetic complications at baseline.
Sensitivity analyses were performed by varying the main cost
factors by 25%. RESULTS: Patients (n = 1024, 512 patients
per cohort) were on average 62 years old, with an average BMI
of 30.5 kg/m2. Average duration of diabetes history at study start
was eight years with an average duration of insulin pre-treatment
of seven months. The average unadjusted total costs per patient
from the SHI perspective per 20-month period were €3114.02
[95% CI 2907.12–3320.93] for Insulin glargine-based vs.
€3439.54 [95% CI 3204.85–3674.23] for NPH-based therapies.
The major cost drivers for both cohorts were insulin utilization,
physician visits and blood glucose monitoring. Average adjusted
total costs per patient were statistically different between Insulin
glargine-based (€2068.55) and NPH-based therapies (€2679.77),
20-month period, p = 0.0004, resulting in adjusted savings of
€611.22 in favor of Insulin glargine based therapies. The eco-
nomic advantage for Insulin glargine-based therapies remained
stable in sensitivity analyses. CONCLUSIONS: LIVE-SPP cost
analyses indicate that Insulin glargine-based therapies offer an
economic advantage over NPH-based therapies, resulting in
potential cost savings.
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OBJECTIVES: To assess the costs incurred in management and
follow-up of severe hypoglycaemic events (SHEs; requiring
external help for recovery) in Germany, Spain and the UK.
METHODS: In 639 people aged 16 years and receiving insulin
for type 1 (n = 319) or type 2 diabetes (n = 320) who experienced
1 SHE in the previous 12 months, health care resource use was
measured for the most recent event via patient surveys. Patients
were grouped by where the SHE was treated: Group 1, commu-
nity (lay person); Group 2, community (health care professional,
HCP); Group 3, hospital. Costs were calculated by applying unit
costs from published sources to estimated resource use; costs per
SHE were calculated by dividing by the number of patients per
subgroup. Weighted average costs across all treatment groups
were derived using prevalence data from the Roper Starch data-
base. RESULTS: Hospital treatment is a major cost driver for
SHEs in all countries, despite most patients being treated in the
community. Costs per SHE were similar for type 1 and type 2
patients in all three countries, e.g. in Germany (Groups 1–3
respectively), €52, €482 and €3671 for type 1 diabetes and €30,
€354 and €3366 for type 2 diabetes. The average cost per SHE
(all patients) for Germany, Spain and UK respectively was €522,
€466 and UK£164 (€242*) in type 1 patients and €595, €572 and
UK£358 (€527*) in type 2 patients (*€1.00 = UK£0.679; average
rate, 2/06–3/07). More patients with Type 2 than Type 1 diabetes
are treated by HCPs in the UK, resulting in higher costs. Calls
and visits to family doctors, additional glucose testing and edu-
cation about diabetes management contribute substantially to
total costs in non-hospitalised patients. CONCLUSIONS: SHEs
add signiﬁcantly to health care costs. SHE treatment costs were
similar in all three countries, despite differences in management
approach.
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OBJECTIVES: The United States (U.S.) Orphan Drug Act (1983)
and the European Union (EU) orphan drug legislation (2000)
established several incentives to encourage the development of
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